HDAC6 and chronic obstructive pulmonary disease: HDAC6 can activate the expression of actin (ERK) in the airway and induce pulmonary vascular remodelling in COPD, while HDAC6 inhibitors can significantly inhibit airway remodelling and increase airway resistance induced by cigarette smoke (CSE) in COPD rats [49].